MYL News and Press, Mylan N.V. From 02/27/20

Mylan (NASDAQ: MYL) was down by almost 4% in after-market trading on Thursday, following the release of its Q4 of fiscal 2019 results in late afternoon.  The pharmaceutical giant managed to raise its total revenue by 4% on a year-over-year basis during the quarter, to $3.19 billion. ...

Mylan (NASDAQ: MYL ): Q4 Non-GAAP EPS of $1.40 beats by $0.12 ; GAAP EPS of $0.04 misses by $0.63 . Revenue of $3.19B (+3.6% Y/Y) misses by $30M . Press Release More news on: Mylan N.V., Earnings news and commentary, Healthcare stocks news,

HERTFORDSHIRE, England and PITTSBURGH , Feb. 27, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the fourth quarter and the year ended December 31, 2019 and provided 2020 guidance. Fourth Quarter 2019 Financial Highlights Total revenue...

HERTFORDSHIRE, England and PITTSBURGH and NEW YORK , Feb. 27, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Pfizer (NYSE: PFE) today announced that Sanjeev Narula , current chief financial officer (CFO) of Upjohn, a division of Pfizer, has been named incoming CFO of Viatris, the ...

13 Inaugural Directors Bring Wide-Ranging Experience, Expertise and a Focus on Driving Shareholder Value Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced the remaining appointees to the inaugural 13-member Board of Directors for Viatris, the new company that will ...

Health insurance, hospitals and drug names all trade sharply lower following Bernie Sanders' convincing win in the Nevada caucuses ( XLV -2.4% ). More news on: Health Care Select Sect SPDR ETF, Molina Healthcare, Inc., Centene Corporation, Healthcare stocks news, Stocks on the move, To...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...

Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

The Food and Drug Administration's Office of Generic Drugs had a productive 2019, approving 1,014 generic drugs, down ever so slightly from the 1,021 it approved in 2018. The 2019 figure includes 110 approvals for generic versions of complex drugs, which are harder to manufacture and typica...

Summary Only 6.5 months have gone by since we assigned a BUY rating to Teva Pharmaceutical Industries Ltd (TEVA) and the stock hasn't disappointed us. A total return of 54.1% isn't only a phenomenal return for itself, but it also significantly outperformed the performance of benchmarks s...